Artios Pharma
Hakan is a Senior Investment Director at Merck Ventures, the corporate venture arm of the biopharmaceutical division of Merck KGaA, having joined the company in 2013. Previously, he was a partner at Aescap Venture in Amsterdam and prior to that at Atlas Venture in London.
Hakan has global investment and deal flow experience, and was instrumental in the creation, financing and development of business and R&D strategies for various companies including Orphazyme-DK, f-Star NL, Protaffin- Austria/UK, Bicycle Therapeutics -UK, Nimbus Discovery -US, Lumavita -CH, Nitec now Horizon Pharma -CH/US, and Egalet -DK. He is currently a board member of Asceneuron, Forendo Pharma, Raze Therapeutics, Tocopherx, Synaffix, and Storm Therapeutics.
Hakan gained his PhD in oncology from the Institute of Cancer Research/ University of London, UK and was post-doctoral fellow at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital.
This person is not in the org chart
This person is not in any offices
Artios Pharma
2 followers
Artios Pharma is a company focused on developing novel cancer treatments targeting the DNA Damage Response #DDR